In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer

Thyroid

Volumn 23, Issue 12, 2013, Pages 1569-1577

  Bentzien, Frauke ^a   Zuzow, Marcus ^a   Heald, Nathan ^a   Gibson, Anna ^a   Shi, Yongchang ^a   Goon, Leanne ^a   Yu, Peiwen ^a   Engst, Stefan ^a   Zhang, Wentao ^a   Huang, Donghui ^a   Zhao, Lora ^a   Vysotskaia, Valentina ^a   Chu, Felix ^a   Bautista, Rajana ^a   Cancilla, Belinda ^a   Lamb, Peter ^a   Joly, Alison H ^a   Yakes, F Michael ^a  

^a EXELIXIS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; CALCITONIN; PROTEIN RET; SCATTER FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CALCITONIN BLOOD LEVEL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SIZE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TOLERABILITY; ENZYME PHOSPHORYLATION; FEMALE; GENE MUTATION; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TISSUE MICROARRAY; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANILIDES; ANIMALS; CARCINOMA, MEDULLARY; CELL LINE, TUMOR; CELL PROLIFERATION; MICE; MICE, NUDE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; PROTO-ONCOGENE PROTEINS C-RET; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84885638118     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0137     Document Type: Article

References (54)

1. Jemal A, Siegek R, Ward E, Hao Y, Xu J, Thun MJ 2009 Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Johanson V, Ahlman H, Bernhardt P, Jansson S, Kolby L, Persson F, Stenman G, Sward C, Wangberg B, Stridsberg M, Nilsson O 2007 A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis. Endocr Relat Cancer 14: 433-444. (Pubitemid 47242641)
3. Roman S, Mehta P, Sosa JA 2009 Medullary thyroid cancer: early detection and novel treatments. Curr Opin Oncol 2: 5-10.
4. Moura MM, Cavaco BM, Pinto AE 2009 Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 100: 1777-1783.
5. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S. 1985-1995. Cancer 83:2638- 2648. (Pubitemid 29019586)
6. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, SchlumbergerM, Bigorgne JC, Dumontier P, Leclerc L, Corcuff B, Guilhem I 1998 Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol 48: 265-273. (Pubitemid 28137636)
7. Leboulleux S, Baudin E, Travagli JP, Schlumberger M 2004 Medullary thyroid carcinoma Clin Endocrinol 61: 299-310. (Pubitemid 39287058)
8. Lodish MB, Stratakis CA 2008 RET oncogene in MEN2, MEN2B, MTC, and other forms of thyroid cancer: molecular genetics and therapeutic advances. Expert Rev Anticancer Ther 8: 625-632. (Pubitemid 351818356)
9. Fialkowski EA, Moley JF 2006 Current approaches to medullary thyroid cancer, sporadic and familial. J Surg Oncol 94: 737-747. (Pubitemid 44902074)
10. Sherman SI 2009 Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 94: 1493-1499.
11. Moley JF, Debenedetti MK, Dilley WG, Tisell LE, Wells SA 1998 Surgical management of patients with persistent or recurrent medullary thyroid cancer. J Intern Med 243: 521-526. (Pubitemid 28312251)
12. Moley JF, DeBenedetti MK 1999 Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 229: 880-887.
13. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE, Evans DB 2005 RET protooncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15: 531-544. (Pubitemid 40993726)
14. Arighi E, Borrello MG, Sariola H 2005 RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 16: 441-467. (Pubitemid 41022013)
15. Mian C, Pennelli G, Barollo S, Cavedon E, Nacamulli D, Vianello F, Negro I, Pozza G, Boschin IM, Pelizzo MR, Rugge M, Mantero F, Girelli ME, Opocher G 2011 Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinol 164: 971-976.
16. Nikiforov YE 2008 Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 21:S37-S43. (Pubitemid 351592770)
17. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A. 2008 Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93: 682-687. (Pubitemid 351398539)
18. Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, Martino E, Romeo G, Pacini F. 1996 Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Endocrinol Metab 81:1619- 1622. (Pubitemid 26118602)
19. Romei C, Mariotti S, Fugazzola L, Taccaliti A, Pacini F, Opocher G, Mian C, Castellano M, Uberti E, Ceccherini I, Cremonini N, Seregni E, Orlandi F, Ferolla P, Puxeddu E, Giorgino F, Colao A, Loli P, Bondi F, Cosci B, Bottici V, Cappai A, Pinna G, Persani L, Uberta V, Boscaro M, Castagna MG, Cappelli G, Zatelli MC, Faggiano A, Francia G, Brandi ML, Falchetti A, Pinchera A, Elisei R; ItaMEN Network 2010 Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol 163: 301-308.
20. Lanzi C, CassinelliG,Nicolini V, Zunino F 2009 Targeting RET for thyroid cancer therapy. Biochem Pharmacol 77: 297-309.
21. Schilling T, Buerck J, Sinn HP, Clemens A, Otto HF, Hoeppner W, Herfarth C, Ziegler R, Schwab M, Raue F 2001 Prognostic value of codon 918 (ATG/ACG) RET protooncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 95: 62-66.
22. Ye L, Santarpia L, Gagel RF 2009 Targeted therapy for endocrine cancer: the medullary thyroid carcinoma paradigm. Endocr Pract 15: 597-604.
23. Oyama T, Ichimura E, Sano T, Kashiwabara K, Fukuda T, Nakajima T 1998 c-Met expression of thyroid tissue with special reference to papillary carcinoma. Pathol Int 48: 763-768. (Pubitemid 28455693)
24. Ramirez R, Hsu D, Patel A, Fenton C, Dinauer C, Tuttle RM, Francis GL 2000 Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (c-MET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clin Endocrinol 53: 635-644.
25. Papotti M, Olivero M, Volante M, Negro F, Prat M, Comoglio PM, DiRenzo MF 2000 Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocr Pathol 11: 19-30. (Pubitemid 30307941)
26. Rong S, Segal S, Anver M, Resaui JH, Vande Woude GF 1994 Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatcyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci USA 91: 4731-4735. (Pubitemid 24177723)
27. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, Comoglio PM 2004 Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6: 61-73. (Pubitemid 38903162)
28. Christensen JG, Burrows J, Salgia R 2005 c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 225: 1-26. (Pubitemid 40732764)
29. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF 2003 MET, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925. (Pubitemid 37493640)
30. Cassinelli G, Favini E, Degl'Innocenti D, Salvi A, De Petro G, Pierotti MA, Zunino F, Borrello MG, Lanzi C 2009 RET/ PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation. Neoplasia 11: 10-21.
31. Asai N, Iwashita T, Matsuyama M, Takahashi M 1995 Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15:1613- 1619.
32. Michiels FM, Chappuis S, Caillou B, Pasini A, Talbot M, Monier R, Lenoir GM, Feunteun J, Billaud M 1997 Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. Proc Natl Acad Sci USA 94: 3330-3335. (Pubitemid 27157311)
33. Accornero P, Lattanzio G, Mangano T, Chiarle R, Taulli R, Bersani F, Forni PE, Miretti S, Scuoppo C, Dastru W, Christensen JG, Crepaldi T Ponzetto C 2008 An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors. Clin Cancer Res 14: 2220-2226. (Pubitemid 351551135)
34. Acton DS, Velthuyzen D, Lips CJ, Höppener JW 2000 Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice. Oncogene 19: 3121-3125. (Pubitemid 30438470)
35. Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, Garcia YK, Min YD, Grossman RF, Siperstein AE, Clark OH 1997 Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 82: 3741-3747. (Pubitemid 27509365)
36. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, Fedele M, Ippolito P, Chiappetta G, Botti G 1995 Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11: 1569-1579.
37. Belletti B, Ferraro P, Arra C, Baldassarre G, Bruni P, Staibano S, De Rosa G, Salvatore G, Fusco A, Persisco MG, Viglietto G 1999 Modulation of in vivo growth of thyroid tumor derived cell lines by sense and anti-sense vascular endothelial growth factor gene. Oncogene 18: 4860-4869. (Pubitemid 29423569)
38. Capp C, Wajner SM, Sigueira DR, Brasil BA, Meurer L, Maia AL 2010 Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 20: 863-871.
39. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird D, Engst S, Lee L, Lesch J, Chou Y-C, Joly AH 2011 Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10: 2298-2308.
40. Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, Tabruyn SP, You WK, Chapman HA, Christensen JG, Aftab DT, McDonald DM 2012 Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2: 270-287.
41. You WK, Sennino B, Williamson CW, Falcon B, Hashizume H, Yao LC, Aftab DT, McDonald DM 2011 VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 71: 4758-4768.
42. Bannen LC, Chan D, Chen J, Dalrymple LE, Forsyth TP, Huynh TP, Jammalamadaka V, Khoury RG, Leahy JW, Mac MB, Mann G, Mann LW, Nuss JM, Parks JJ, Takeuchi CS, Wang Y, Xu W 2005 c-Met modulators and methods of use. PCT Int Appl O 2005030140 A2 20050407.
43. Carlemagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, Billaud M, Santoro M 2004 Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23: 6056-6063. (Pubitemid 39178858)
44. Carlomagno F, Salvatore D, Santoro M, de Franciscis V, Quadro L, Panariello L, Colantuoni V, Fusco A 1995 Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 207: 1022-1028.
45. Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G Seregni E, Martinetti A, Laccabue D, Zanchi C, Zunino F 2004 Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst 96:1006- 1014. (Pubitemid 39162643)
46. Perez CA, Arango BA, Velez M, Raez LE, Santos ES 2012 Emerging role of multikinase inhibitors for refractory thyroid cancer. Biologics 6: 257-265.
47. Ivan M, Bond JA, Prat M, Comoglio PM, Wynford-Thomas D. 1997 Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 14: 2417-2423. (Pubitemid 27268160)
48. Boichard A, Croux L, Al Ghuzlan A, Broutin S, Dupuy C, Leboulleux S, Schlumberger M, Bidart JM, Lacroix L 2012 Somatic RAS mutations occur is a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab 97: 2031-2035.
49. Ciampi R, Mian C, Fugazzola L, Cosci B, Romei C, Barollo S, Cirello V, Bottici V, Marconcini G, Rosa PM, Borrello MG, Basolo F, Ugolini C, Materazzi G, Pinchera A, Elisei R. 2013 Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid 23: 50-57.
50. Veerbeek HHG, Alves MM, de Groot J-WB, Osinga J, Plukker JTM, Links TP, Hofstra RMW 2011 The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab 96: 991-995.
51. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Muller T, Ratain MJ, Salgia R 2011 Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid carcinoma. J Clin Oncol 29: 2660-2666.
52. Schöffski P, Elisei R, Müller S, Brose MS, Shah MH, Licitra LF, Jarzab B, Medvedev V, Kreissl M, Niederle B, Cohen EW, Wirth LJ, Ali HY, Hessel C, Yaron Y, Ball DW, Nelkin B, Sherman SI, Schlumberger M. 2012 An international, doubleblind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. Abstract presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, June 1-5. Abstract no 5508.
53. Fagin JA 2002 Perspective: lessons learned from molecular genetic studies of thyroid cancer - insights into pathogenesis and tumor-specific therapeutic targets. Endocrinology 143: 2025-2028. (Pubitemid 34521548)
54. Cabanillas ME, Brose MS, Ramies DA, Lee Y, Miles D, Sherman SI 2012 Antitumor activity of cabozantinib (XL184) in a cohort of patients with differentiated thyroid cancer (DTC) Abstract presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, June 1-5. Abstract no 5547.